ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGN

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Organon & Co. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the Organon securities lawsuit is from October 31, 2024, to April 30, 2025, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must file a motion with the court by July 22, 2025, to represent other class members [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Organon's management made misleading statements about the company's priorities, particularly regarding capital allocation and dividend payments [4]. - It is claimed that the company concealed the importance of its debt reduction strategy, which led to a 70% decrease in the regular quarterly dividend following the acquisition of Dermavant [4]. - The lawsuit asserts that investors suffered damages when the true information about the company's financial priorities became public [4].